ADCT — ADC Therapeutics SA
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-05-15.
Performance
Technicals
Others in Healthcare
Measured signals that fired on ADCT
| date | signal | measured base rate |
|---|---|---|
| 2026-08-12 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-04-02 | Cluster sale: three or more insiders insider | -0.37% over 21 days · t = -3.38 · n = 21,542 statistically distinguishable from its control group |
| 2026-03-10 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-30 | GRAHAM PETER J Chief Legal Officer | Grant or award | 221.1K | 0.00 | 0 |
| 2026-06-30 | Zaki Mohamed Chief Medical Officer | Grant or award | 213.9K | 0.00 | 0 |
| 2026-06-30 | Carmona Jose Chief Financial Officer | Grant or award | 203.7K | 0.00 | 0 |
| 2026-06-30 | MALLIK AMEET Chief Executive Officer | Grant or award | 675.0K | 0.00 | 0 |
| 2026-06-03 | Squarer Ron Director | Shares withheld for tax | 15.2K | 3.08 | 46.8K |
| 2026-06-03 | Coughlin Timothy Director | Shares withheld for tax | 12.6K | 3.08 | 38.8K |
| 2026-06-03 | Sandor Victor Director | Shares withheld for tax | 12.6K | 3.08 | 38.8K |
| 2026-06-03 | BIZZARI JEAN-PIERRE Director | Shares withheld for tax | 12.6K | 3.08 | 38.8K |
| 2026-06-03 | Azelby Robert Director | Shares withheld for tax | 12.6K | 3.08 | 38.8K |
| 2026-06-03 | Monges Viviane Director | Shares withheld for tax | 2.6K | 3.08 | 8.0K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Redmile Group, LLC | 58.0M | 15.5M |
| TCG Crossover Management, LLC | 42.7M | 11.4M |
| Prosight Management, LP | 31.1M | 8.3M |
| BlackRock, Inc. | 23.4M | 6.3M |
| EVENTIDE ASSET MANAGEMENT, LLC | 21.4M | 5.7M |
| Nantahala Capital Management, LLC | 21.0M | 5.6M |
| MORGAN STANLEY | 14.3M | 3.8M |
| Point72 Asset Management, L.P. | 12.7M | 3.4M |
| MILLENNIUM MANAGEMENT LLC | 11.7M | 3.1M |
| GOLDMAN SACHS GROUP INC | 6.2M | 1.7M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript · 2026-08-20
- Adc Therapeutics SA (ADCT) filed form 8-K · 2026-08-13 · SEC EDGAR
- ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates · 2026-08-13
- ADC Therapeutics Q2 Earnings Preview · 2026-08-12
Ask the AI about ADCT
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →